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Abstract  
 
POEMS syndrome is a rare and disabling autoinflammatory condition, typified by 
a typical peripheral neuropathy and the presence of a monoclonal plasma cell 
disorder. The acronym ‘POEMS’ represents the complex and multi-system 
features of the disease, including polyneuropathy, organomegaly, 
endocrinopathy, a monoclonal plasma cell disorder, and skin disease. The 
diagnosis of POEMS is a significant challenge because of the heterogeneity of 
clinical presentations and variation of POEMS features. Patients are often 
misdiagnosed with another cause of inflammatory neuropathy and receive one 
or more ineffective immunomodulatory medications resulting in delayed 
diagnosis and further clinical deterioration before a diagnosis is made. 
 
University College London Hospital sees one of the largest reported POEMS 
cohorts in Europe, and runs a multi-specialist clinic to assist with diagnosis, 
treatment and ongoing support. This review draws upon our experience to 
present the typical features of POEMS syndrome, and highlight diagnostic 
conundrums commonly experienced supplemented with clinical cases. We will 
provide an investigative guide for clinicians when considering POEMS as the 
diagnosis, and propose a treatment algorithm which centres on the site and 
degree of monoclonal cell proliferation.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
POEMS syndrome, first coined by Bardwick in 1980, is an acronym to describe 
the clinical phenotype of a rare and disabling multisystem, autoinflammatory 
condition featuring polyneuropathy, organomegaly, endocrinopathy, the 
presence of a monoclonal plasma cell disorder and skin disease 1. Larger cohort 
studies have revealed several other characteristic findings, including 
papilloedema, extravascular volume overload, sclerotic bone lesions and 
thrombocytosis (abbreviated to ‘PEST’ as a supplementary aide memoire 2). The 
pathogenesis of POEMS syndrome is not understood, but is thought to be related 
to the monoclonal plasma cell proliferative disorder and the impact this has on 
inducing a cytokine driven inflammatory response 3–7. Vascular endothelial 
growth factor (VEGF), a potent angiogenic cytokine, was found to be markedly 
raised in the serum of POEMS patients 8. Reported treatment trials blocking 
VEGF with bevacizumab resulted in worsening of neuropathy and some 
deaths9,10. This suggests although VEGF is a useful biomarker for disease 
detection and monitoring  3,4,8,11, its role in pathogenesis is poorly understood.  
 
Dispenzieri et al proposed the widely accepted diagnostic criteria in 2003 in an 
attempt to standardise the number of features and investigation findings 
necessary to make a diagnosis of POEMS syndrome 2 (see table 1). 
Polyneuropathy and a monoclonal plasma cell disorder are hallmarks of the 
clinical disease, and therefore mandatory criteria for diagnosis.  As is typical in 
medicine, textbook definitions very rarely reflect what is seen in clinical practice. 
Although there are clear diagnostic criteria, POEMS syndrome remains 
notoriously difficult to diagnose. Despite the presence of a monoclonal lambda 
light chain plasma cell dyscrasia in 95% of cases 13 coupled with the highly 
sensitive biomarker VEGF 4, misdiagnosis remains likely. The heterogeneity of 
clinical presentations, with patients commonly presenting with only a limited 
number of the features described contributes to the diagnostic difficulties. The 
subtlety or lack of bone marrow abnormality provides false reassurance of the 
absence of a monoclonal plasma cell disorder.  The typically inflammatory 
neuropathy mimics that of the much more familiar chronic inflammatory 
demyelinating polyneuropathy (CIDP); over 60% of patients are initially 
diagnosed as CIDP 14, resulting in treatment with ineffective immunomodulatory 
therapy and subsequent clinical deterioration due to delayed diagnosis by a 
median of 12 months 14. Features such as endocrinopathy, papilloedema and skin 
conditions are non-specific, and may not typically be attributed to a neurological 
syndrome. Furthermore, investigations may be misinterpreted or down-played, 
resulting in reports which may not synthesise the whole picture. With all the 
diagnostic uncertainty and misleading information in such a complex disease, it 
is little wonder clinicians fail to consider the diagnosis.  
 
Once the diagnosis is made, uncertainties still remain regarding treatment. 
Treatment is directed at the underlying clonal plasma cell disorder and depends 
on the distribution of the disease and extent of bone marrow involvement. Novel 
chemotherapeutic agents and autologous stem cell transplantation allow for 
significant improvement of disease free survival. However, treatment selection, 
assessing response, accurately monitoring disease and identifying relapses is 
complex and requires multiple investigational modalities. Indeed, the 
multisystem nature of POEMS and its compounding disabilities requires multi-
disciplinary support and assistance.   
 
This review aims to guide clinicians through the diagnostic process towards 
making a diagnosis of POEMS syndrome. We describe the ‘typically atypical’ 
POEMS patient, and illustrate some of the diagnostic conundrums of POEMS 
using case examples. We provide recommendations for the thorough 
investigative workup required to diagnose POEMS syndrome, and the commonly 
misreported findings to look out for.  A treatment guideline is proposed, and 
recommendations for monitoring patients and identifying relapses is provided.  
 
The typically atypical presentation of POEMS syndrome  
Neuropathy  
The diagnostic criteria for POEMS syndrome are displayed in table 1. The 
presence of polyneuropathy and a monoclonal plasma cell disorder are 
fundamental to the diagnosis. The polyneuropathy in POEMS syndrome shares 
many similar characteristics to CIDP, with development of a subacute, 
progressive motor predominant polyradiculoneuropathy. Both conditions 
display albuminocytological dissociation on cerebrospinal fluid analysis and 
electrophysiological evidence of demyelination with f-wave prolongation, slowed 
conduction velocity and temporal dispersion. However, the neuropathies are 
very different and clues in the history, examination and neurophysiological 
findings to distinguish POEMS neuropathy from CIDP are detailed in see table 2. 
In practice, neurophysiology results may be misinterpreted and reported as 
fitting diagnostic criteria for CIDP 15, and for this reason we recommend all 
patients presenting with an inflammatory neuropathy to have appropriate 
investigations for the presence of a monoclonal plasma cell proliferative disorder 
(serum and urine protein electrophoresis, immunofixation and serum free light 
chain assay), and consideration of VEGF included at the outset, and certainly if 
there is a lambda light chain paraprotein. The finding of a lambda light chain 
and/or a raised VEGF should prompt further thorough investigation, detailed 
below. The neurohistopathology of POEMS nerves is of  axonal and 
demyelinating lesions with uncompacted myelin lamellae 16,17. Uncompacted 
myelin is non-specific, and with much more sensitive biomarkers such as a 
monoclonal proliferative disorder with lambda light chains and raised VEGF 3,4, 
we do not recommend nerve biopsy to distinguish POEMS from CIDP. It may 
however be indicated to rule out suspected vasculitis, amyloid or an infiltrative 
disorder, all of which may cause a painful or non-steroid or IVIG responsive 
neuropathy like POEMS. 
 
 
 
Monoclonal plasma cell disorder  
Once POEMS syndrome is considered, the presence of a monoclonal plasma cell 
disorder must be proven to make the diagnosis. This requires detection of 
monoclonal proteins (paraproteins) formed by a single heavy chain (M, G or A) 
and a light chain (kappa or lambda) which is usually, but not always secreted. 
Around 10% of patients with polyneuropathy of otherwise unknown cause have 
a monoclonal gammopathy 18. A low level stable paraprotein is not infrequently 
discovered in older persons, and often attributed to an insignificant monoclonal 
gammopathy of unknown significance (MGUS). Interestingly the majority of 
monoclonal gammopathies found in association with neuropathy are IgM (78%) 
and kappa (88%) 19. For reasons unknown, gammopathies in POEMS syndrome 
are characteristically IgA and IgG (52 and 47% respectively) and almost never 
IgM 2. Lambda light chain predominates and is seen in 95% of POEMS cases 2. 
Although IgA or IgG lambda monoclonal proliferation can exist in cases of MGUS, 
this peculiar pattern of heavy and light chain combination should serve as a ‘red 
flag’, strongly alerting clinicians to consider the diagnosis of POEMS or light 
chain amyloidosis.  
 
Demonstration of a monoclonal plasma cell disorder can be through serological 
testing, urine, bone marrow or biopsy specimen histopathology. Serum protein 
electrophoresis (SPE), immunofixation and serum free light chain (SFLC) 
analysis must all be performed to detect a subtle plasma cell disorder with 
appropriate sensitivity. Many haematology laboratories do not provide 
immunofixation and serum free light chain analysis if preliminary investigations 
are unrevealing, and therefore neurologists must work with their laboratories to 
enable such testing as routine for all POEMS suspected cases. An example of this 
in clinical practice is below.  
 
 
Case example 1: The importance of thorough haematological investigations 
A 56 year old male with a background history of treated Castleman’s disease 
presented in 2004 with lower limb neuropathic sounding pain. This progressed 
over 3 years to involve oedema and weakness with bilateral foot drop, and 
neurophysiology revealed a severe sensorimotor neuropathy with axonal loss on 
electromyography (EMG). Six SPE examinations were performed across a 3-year 
period, all of which were negative. In 2007, the first immunofixation was 
performed, and demonstrated a low level IgA lambda paraprotein not visible on 
SPE. This demonstrates the utility of immunofixation. If immunofixation and 
serum free light chain analysis are not performed, a monoclonal paraprotein will 
be missed in about 30% of POEMS cases 2. 
 
Urine protein electrophoresis (UPEP), immunofixation and light chain analysis 
are performed through urine collection, and are often not sent for practical 
reasons. However, a random (as opposed to 24 hour collection) urine sample is 
all that is required to detect monoclonal proteins. The natural homeostatic 
ultrafiltration of urine is a serum free light chain concentrator, and can result in 
patients who are serum negative having positive urine results.  
 
 
Case example 2- The importance of testing the urine 
A 38 year old female presented with a demyelinating neuropathy diagnosed as 
probable CIDP, who had at least three SPE, immunofixation and SFLC 
assessments over two years, all of which were normal. The urinary Bence Jones 
Protein was positive, with free lambda light chains detected by immunofixation. 
By the time of detection, the patient had received prednisolone, 2 courses of 
intravenous immunoglobulin (IVIG), methotrexate and plasma exchange without 
any improvement. We use this example to stress the importance of sending all 
tests, including urine as part of the full investigative workup, where Bence Jones 
Protein or urinary light chains may be the only evidence of a monoclonal plasma 
cell disorder.  
 
 
Bone marrow aspiration and trephine should be performed for 
immunophenotypic evaluation once a monoclonal plasma cell disorder is 
detected serologically or in the urine. Examination of the bone marrow provides 
an invaluable tool in the diagnosis and classification of plasma cell dyscrasias 
and to ascertain extent of disease 20. Two thirds of bone marrow biopsies 
demonstrate a plasma cell malignant clone in POEMS 21 typically at a low level of 
around 5-10%, often with a very high proportion of abnormal cells restricted to 
expressing lambda light chains (≈90%). The presence of bone marrow lymphoid 
aggregates rimmed by monotypic or polytypic plasma cells should lead 
haematopathologists to raise the possibility of POEMS syndrome 21 (see figure 
2). Megakaryocyte hyperplasia and clustering is also seen in POEMS syndrome 
bone marrow histology, and can therefore lead to the misinterpretation of a 
myeloproliferative disorder. However, one third of bone marrow biopsies will 
not demonstrate evidence of a plasma cell clone. This is because the monoclonal 
plasma cell disorder is limited to multifocal or solitary plasmacytomas (a 
discrete solitary mass of neoplastic monoclonal plasma cells in soft tissue or 
bone) 2,21,22. For this reason, a non-diagnostic bone marrow result should 
necessitate further investigation for plasmacytomas through whole body 
imaging such as PET-CT. The CT modality enables sclerotic and lytic lesions to be 
identified and FDG-PET provides pointers to glucose-avid plasmacytomata. The 
most FDG-avid, accessible bone lesion should be biopsied to obtain histological 
confirmation of the diagnosis. The extent and location of monoclonal plasma cell 
disorder influences treatment decisions and is discussed further.  
 
 
Multi system features 
The wide-ranging multi system features of POEMS are displayed in table 1. 
Endocrine disturbance is seen in 65% of our UK POEMS cohort, with a high 
incidence of hypogonadism and hypopituitarism. Hypogonadism and 
hypopituitarism are most frequently manifested as erectile dysfunction and 
gynaecomastia in men, and early menopausal symptoms in women. The baseline 
prevalence of diabetes and thyroid disease is too high to include as diagnostic 
criteria for POEMS syndrome, unless there is a distinct temporal relationship 
with the onset of symptoms. Organomegaly of the spleen, liver or lymph nodes is 
detected in around 50% of our cohort. Red flags that should alert neurologists to 
the diagnosis of POEMS syndrome include ‘glomeruloid haemangiomata’; dome 
shaped red-brown papular (sometimes pedunculated) nodules on the trunk or 
proximal extremities which are thought to develop secondary to overexpression 
of VEGF (see figure 1). Papilloedema is rare in inflammatory neuropathy 23 so 
when discovered should trigger investigation for POEMS syndrome where it is 
seen in around 40% 2. If it is severe enough to be haemorrhagic, the 
haemorrhage is subretinal and very striking (see figure 1). Neuropathy in a 
young patient with unexplained peripheral oedema and skin changes suggesting 
capillary leak does not occur in CIDP and again are clinical clues to POEMS 
syndrome. Capillary leakage also occurs in the lungs, abdomen and heart 
resulting in poor gas transfer, ascites and pericardial effusions in severely 
affected patients. 
 
Patients rarely present with the perfect cluster of symptoms described in the 
POEMS acronym. We have seen a variety of patients with POEMS variants and 
will present two examples below.  
 
Case example 3- POEMS without the ‘P’ 
A 45 year old male presented with a two year history of pain in the right lower 
limb on walking. Investigations revealed compression of the right femoral artery 
with lymphadenopathy, which on biopsy was reported as ‘reactive changes’. He 
was suspected of having Castleman disease, but a repeat biopsy of another node 
to look for evidence for this was reported as reactive, with no evidence of 
Castleman’s. An IgA lambda paraprotein was found on SPE/immunofixation, in 
association with an endocrinopathy with low testosterone. Serum VEGF was 
more than 5000pg/ml (ref range 5-771pg/ml).  PET imaging revealed 
osteosclerotic lesions throughout the spine. A bone marrow trephine contained 
more than 15% plasma cells. Clinical examination revealed several glomerular 
haemangiomata on the trunk. Apart from pain in the lower right leg which was 
likely vascular in origin, there were no neuropathic symptoms in the limbs. 
Clinical examination and neurophysiology demonstrated no evidence of a 
neuromuscular disorder. The patient was diagnosed with POEMS syndrome 
based on the multitude of findings, but strictly does not fit the diagnostic criteria 
due to absence of polyneuropathy. The patient is awaiting an autologous stem 
cell transplant as first line therapy.  
 
Case example 4- ‘*O*MS’  
This patient presented following a seizure and was found to have had a left 
occipital stroke. During the investigation, both thrombocytosis and a raised 
haematocrit were noted, with negative myeloproliferative genetic tests (Jak2 and 
Cal-R mutations). An IgG lambda paraprotein was detected on SPE. A bone 
marrow biopsy revealed a 15% lambda-restricted plasma cell clone. Imaging 
revealed multiple lymph nodes and an L4 sclerotic lesion. Acrocyanosis of the 
peripheries was noted on clinical examination. There was no evidence of 
endocrinopathy. The sVEGF was markedly elevated at 11,000pg/ml (ref range 5-
771pg/ml). The patient had no clinical or electrophysiological evidence of 
neuropathy. Lymph node biopsy revealed angiofollicular lymph node 
hyperplasia, consistent with Castleman’s disease. Treatment with 5 cycles of 
lenalidomide, cyclophosphamide and dexamethasone was completed, to be 
followed by autologous stem cell transplantation. A recent PET scan has shown 
resolution of lymph nodal disease and sVEGF of 1074pg/ml after 4 cycles of 
lenalidomide and dexamethasone. 
 
Castleman’s disease is a lymphoproliferative disorder, which can be limited to a 
single group of lymph nodes (unicentric) or multiple lymph nodes and organs 
such as the spleen and thymus (multicentric). Castleman’s can be present in up 
to 30% POEMS cases 24 on lymph node biopsy. POEMS patients with Castleman’s 
are said to have less severe neuropathy, which may explain why there can be 
such heterogeneity. Other cases of atypical POEMS have been reported in the 
literature with an argument to redefine the diagnostic criteria and include the 
entity of Castleman’s Disease Variant of POEMS 25. An atypical presentation of 
POEMS with a positive VEGF is probably more likely to be POEMS than another 
disease, and therefore VEGF is a useful test when faced with an atypical 
presentation. Guidance on interpreting results such as this is available through 
specialist clinics.  
 
 
Investigating POEMS syndrome 
 
Extensive investigations are required to confirm the presence or absence of a 
multitude of systemic features at diagnosis, during monitoring and following 
treatment.  We propose an investigative guideline in table 3. Skeletal surveys and 
CT chest, abdomen and pelvis can be useful to identify mixed sclerotic and lytic 
bone lesions, but involve significant irradiation. Whole body MRI is often 
employed as a screening tool and PET CT is the most useful imaging modality to 
identify FDG-avid plasmacytomas or lymph nodes for biopsy. 
 
The role of VEGF  
VEGF has been proven to be a highly accurate surrogate biomarker of disease 
detection and activity in POEMS. Plasma and serum levels are markedly elevated 
compared to patients with other plasma cell dyscrasias (P<0.001), peripheral 
neuropathy (P<0.001) and connective tissue disease/vasculitis (P<0.009) 26,27.  
Hypoxia, anaemia and low iron can lead to false positive results, but rarely as 
high as POEMS positive samples, which are 2 to 3 times the upper limit of normal 
27. False negative results can occur from patients treated within the last month 
with steroids and should be interpreted with caution 6,10.  Serum VEGF levels are 
10-50 times higher than that of plasma in both health and disease, as serum 
contains VEGF released by ex vivo platelet activation during the clotting process, 
as well as the serum 6. Both tests are similarly useful in the diagnosis and 
monitoring of POEMS, but for clarity, we advise using either the serum or the 
plasma for each patient and not both. Levels displayed in this paper are all serum 
VEGF.  
 
Case example 5: Anaemia and low iron induces VEGF production 
This 20 year old mechanic presented with acute global weakness following a 
sore throat, diagnosed as Guillain-Barré Syndrome. IVIG was initiated and the 
patient improved and was able to return to work. For the following year he 
experienced relapses on a two monthly basis. Each episode was responsive to 
steroids, IVIG or PLEX. Neurophysiology demonstrated a demyelinating 
polyradiculoneuropathy. There was albuminocytologic dissociation on CSF 
analysis. MRI revealed thickened nerve roots. No monoclonal paraprotein was 
detected by SPE, immunofixation or SFLC analysis. PET was normal. There were 
no bone lesions on imaging. Clinically there was no evidence of POEMS features 
other than neuropathy. A diagnosis of CIDP was made. A sVEGF was taken, and 
was found to be significantly raised at 1627pg/ml. A repeat sample result, 5 
months after the first, was 2615 pg/ml. Bone marrow biopsy was then 
performed which was normal. Persistent iron deficiency anaemia was noted 
despite oral supplementation. Iron deficiency was thought to be driving the high 
sVEGF, and therefore was treated more aggressively with intravenous iron 
following normal endoscopy and colonoscopy. Subsequently, the sVEGF level 
dropped to 800pg/ml after 4 months, and is due further testing in due course.  
 
 
Case example 6: Hypoxia induces VEGF production 
A 55 year old female presented with a 10 month history of progressive 
weakness, numbness and pain in the distal lower limbs was diagnosed with 
POEMS following bone marrow biopsy and a sVEGF of 5657 pg/ml. Lenalidomide 
and dexamethasone was selected as initial treatment with co-trimoxazole 
prophylactic cover. Within one month of treatment, sVEGF reduced from 5657 to 
599 pg/ml. The patient developed a rash, and co-trimoxazole stopped and 
dapsone initiated. Subsequently the patient developed methaemoglobinaemia 
secondary to dapsone, inducing hypoxia. sVEGF increased at this time to 
1303pg/ml. Dapsone was stopped and the sVEGF rapidly normalised. See figure 
3 for details.  
 
 
Both cases illustrate that despite VEGF being highly sensitive and specific for 
POEMS syndrome, iron deficiency and hypoxia induce VEGF production so 
should be considered as a possible contributing factor when one is faced with 
abnormal values close to the upper limit of normal (ref range 5-771pg/ml). 
There have been other reported cases of patients with high false positive VEGF 
results such as in connective tissue disease and vasculitis 6. For this reason, the 
VEGF level should be interpreted in the context of a typical POEMS neuropathy 
and a lambda light chain plasma cell dyscrasia to diagnose POEMS.   
 
 
 
Treating POEMS syndrome 
 
Despite VEGF being a sensitive biomarker of POEMS syndrome, trials of the anti-
VEGF monoclonal, bevacizumab, yielded ineffective, if not detrimental results 
9,10.  The mainstay of treating POEMS syndrome is therefore through suppression 
of the monoclonal plasma cell proliferation. This can be done in a number of 
ways, and depends on the extent of disease, co-morbidities and patient fitness.  
 
As mentioned before, the monoclonal plasma cell disorder can consist of diffuse 
bone marrow infiltration, and/or solitary/ multifocal plasmacytomata. Patients 
with bone marrow involvement on bone marrow biopsy, or three or more 
plasmacytomas are considered to have systemic disease; two or fewer 
plasmacytomas is considered focal disease. Figure 4 provides a treatment 
algorithm dependent on the extent of disease.  
 
Focal disease (One or two plasmacytomata) 
Radiotherapy to two or fewer plasmacytoma lesions is first line treatment in 
focal disease. The objective is to obtain complete remission with minimal side 
effects whilst avoiding protracted treatment when compared to systemic 
therapies. From 67 patients with POEMS at the UCLH service, 22 patients have 
been treated with radiotherapy as first line. Eleven patients went onto have 
second line systemic therapy due to clinical or biochemical relapse, after an 
average of 22 months (median 13 months). Eleven patients have remained 
clinically stable, with our longest surviving patient at 19 years post radiotherapy.  
 
Case example 7- How to treat focal lesions 
A 73 year old male with a background of ischemic heart disease presented in 
2011 with generalised lower limb weakness, and bilateral foot drop. By six 
months the patient was wheelchair bound with little hand movement. Clinical 
examination revealed fluid overload, no evidence of skin lesions, organomegaly 
or papilloedema. Investigations revealed a severe length dependent 
sensorimotor demyelinating neuropathy and he was totally dependent on his 
family for his daily needs. Blood tests revealed evidence of subclinical 
hypothyroidism, and an IgG lambda paraprotein of 3g/L. Cerebrospinal protein 
level was significantly elevated at 2.8 g/L, with no cells. For this reason, a sVEGF 
was performed (11,000pg/ml, normal range 5-771pg/ml).  A skeletal survey and 
follow up PET-CT demonstrated a solitary ‘soap-bubble’ lesion of the proximal 
left femur (see figure 5). A soap-bubble appearance is an expansile, often 
eccentric, vaguely trabeculated space with a thin sclerotic sharply defined 
margin, and usually signifies osteoclastomas/ giant cell tumours of the bone 28. 
Bone marrow aspirate and trephine histology was normal. The femoral lesion 
was biopsied, which demonstrated a CD138 plasma cell infiltrate. The patient 
was given IV methylprednisolone for 3 days to stabilise his condition, resulting 
in an acute coronary syndrome for which he received coronary stents. Due to the 
poor stability of the femoral lesion, an intramedullary nail was inserted, and 25 
fractions (total 50 Gray) radiotherapy was directed at the lesion. The sVEGF 
three months following fell to 506 pg/ml and the patient started to notice 
improved power in the lower limbs. He continues to improve; 5 years post 
radiotherapy the sVEGF has remained in normal limits, repeat imaging of the 
femoral lesion is stable, and the patient can now walk 200 yards with orthotics 
and is independent in activities of daily living.   
 
 
Generalised disease (three or more plasmacytomas or positive bone marrow 
histology) 
Systemic treatment should be used for patients with generalised disease. 
Melphalan conditioned Autologous Stem Cell Transplantation (ASCT) is the gold 
standard, with chemotherapy used for patients deemed unfit for transplantation.  
 
Due to small patient numbers, treatment algorithms for POEMS syndrome have 
been adopted from multiple myeloma or light chain amyloidosis. High dose 
chemotherapy plus ASCT is the current gold standard treatment for POEMS 
syndrome, with good haematological control with progression free survival of 
98%, 94% and 75% at 1, 2 and 5 years 29–31 and good organ-specific response 
levels, with 100% patients achieving ‘a degree of neurological recovery’ 32,33. The 
ASCT for POEMS syndrome at University College London was performed in 1999 
34 for a 56 year old male, who remains in remission, fully ambulant with a most 
recent sVEGF of 276 pg/ml. Thirty-six have been performed subsequently, and 
only three patients have required further treatment with systemic 
chemotherapy.  Age, comorbidities and physiological fitness should be 
considered prior to ASCT. We quote a 5-10% risk of the need for intensive care 
treatment, and 3-5% risk of mortality, depending on performance status 31,35. 
Engraftment syndrome has been quoted to occur in around 20%-50% of patients 
31, however we have not seen this in our cohort of 36 treated patients. Patients 
can relapse, and in such cases, low dose long-term chemotherapy is an option, or 
a second ASCT but evidence is lacking. 
 
Patients not deemed fit for ASCT can be treated with chemotherapeutic agents as 
pre-transplant induction therapy, enabling transplantation at a later date, or long 
term if stem cell transplantation is not an option. Broadly speaking, 
chemotherapy used to be based on an alkylating agent (such as melphalan or 
cyclophosphamide) and dexamethasone 30,36.  Thalidomide and lenalidomide, 
potent inhibitors of tumour secreting cytokines such as interleukin 6, tumour 
necrosis factor and VEGF are emerging as treatments for POEMS syndrome. We 
are now often using lenalidomide as first line therapy. A systematic review of 
lenalidomide in POEMS reported neuropathy improvement in 90% of cases, and 
a progression free survival estimate at 12 months of 93% 37. We have seen 
remarkable rapid improvement in clinical status, particularly in fluid overload, 
VEGF and haematological response using lenalidomide and dexamethasone. 
Peripheral neuropathy with thalidomide, and risk of thrombosis with both 
agents require careful monitoring and the need for prophylactic low molecular 
weight heparin. Bortezomib as a single agent, or combined with 
cyclophosphamide has demonstrated promising results in 25 patients, but can 
also cause or worsen peripheral neuropathy 38.  
 
 
Case example 8- Choosing the correct therapy  
A 69 year old male was suspected of having POEMS syndrome on the basis of 
demyelinating polyneuropathy, fluid overload, skin changes (acrocyanosis and 
hypertricosis) and papilloedema. Investigations revealed an IgG lambda 
paraprotein of 9g/l, sVEGF of 2843pg/dl and a solitary plasmacytoma of the left 
ilium which demonstrated plasma cell infiltration. Bone marrow biopsy of the 
right ilium was normal. Nineteen fractions of local radiotherapy were provided. 
Three months following radiotherapy, the patient was noted to have weight loss 
and worsening neuropathy, and sVEGF had doubled to 4865pg/ml. Disease 
reassessment included a repeat PET-CT scan which demonstrated evidence of 
multifocal skeletal lesions with persistent avidity in the index lesion. 
Retrospective analysis of the original PET scan revealed evidence of bone lesions 
which previously had not been reported. Due to the presence of systemic 
disease, Lenalidomide and Dexamethasone were initiated with prior stem cell 
harvesting with a view to autologous stem cell therapy. Systemic induction 
immunomodulatory therapy was used prior to transplant in an attempt to limit 
the collective volume of multifocal skeletal plasmacytomas.  
 
Disability management  
 
Multi-disciplinary input is essential when caring for patients with POEMS 
syndrome. Disability management through the use of orthotics, walking aids and 
home adaptations should be provided through physiotherapy and occupational 
therapy services, preferably in a multidisciplinary environment. Neuropathy in 
POEMS classically takes around 2-3 years post-treatment before significant 
improvement begins. A retrospective review of 60 POEMS patient post ASCT 
showed a median improvement in the neuropathy impairment score of 18 points 
(66 to 48 points) in 12 months and 30 points at a median follow up of 60 
months.32 We typically refer patients for neuro-rehabilitation both early in 
disease and once neuropathy starts to improve. Educational and emotional 
support can be provided through specialist nurses and psychologists, and we 
refer patients to the POEMS Facebook group (search ‘POEMS syndrome’ on 
Facebook for the page). 
 
 
Monitoring  
 
Assessing response to treatment and monitoring is complex and requires 
thorough investigation and clinical assessment to determine response. Broadly, 
the following categories are used to assess response: 
 
1)  Haematological response: This is defined by the clearance of 
monoclonal proteins and plasma cells from the blood and bone marrow 
respectively. This can be misleading, as the monoclonal component in 
POEMS tends to be very subtle, and patients can improve significantly 
despite the absence of a monoclonal protein response 30.  
2) VEGF: VEGF tends to correlate with disease activity, and should normalise 
(serum level<771pg/ml) over 6 months, but again can show discordance 
with response.  
3) PET-CT imaging: This can be useful to demonstrate reduction in 
standardised uptake values (SUVmax) of previously avid lesions. 
Reductions in SUV take many months (often more than 12). 
4) Organ response: Organ response can be difficult to quantify, but the 
following markers would indicate improvement  
 Reduction in weight secondary to resolution of fluid overload 
 Shrinkage of enlarged organs or lymph nodes 
 Shrinkage or disappearance of glomeruloid haemangiomata 
 Improvement in pulmonary and cardiac function  
 Improvement in neuropathy severity scores such as RODS-CIDP or 
MRC sum scores. 
 
Collating all the above provides an overall picture of the patient’s disease status. 
Any worsening of clinical, radiological or haematological indicators should 
instigate further investigation with the tests highlighted in table 3, ultimately 
with consideration of a bone marrow biopsy where appropriate.   
 
 
Case example 9- Assessing and monitoring response to treatment  
A 72 year old farmer was diagnosed in 2012 with POEMS on the basis of a 
demyelinating peripheral neuropathy, organomegaly, IgG lambda paraprotein of 
6g/dl and a solitary FDG-avid pubic bone lesion on PET-CT imaging. Bone 
marrow biopsy also demonstrated 10% plasma cell infiltration. sVEGF level was 
3917 pg/ml. At the time of diagnosis, the patient was unable to stand. Systemic 
therapy with melphalan and dexamethasone was initiated, and focal 
radiotherapy to the pubic bone lesion was delivered as 30Gy in 10 fractions, 
completed in February 2013. At four months following treatment, repeat PET–CT 
imaging demonstrated no change to the pubic bone lesion, but more 
reassuringly, sVEGF had reduced to 550pg/ml, and paraprotein level had halved 
to 3g/dl. At this stage, repeat bone marrow biopsy was indicated to ascertain the 
degree of residual disease burden. This demonstrated 1% plasma cell 
infiltration, and at six months the patient started to show signs of neuropathy 
improvement in reduction of pain and increased mobility. It was therefore 
decided to continue monitoring at this stage. If the bone marrow was 
persistently abnormal this would indicate ongoing disease, in conjunction with 
the unchanged appearance of the pubic bone lesion, and therefore consideration 
of systemic/immunomodulatory therapy.  Repeat PET imaging one year 
following treatment in February 2014 demonstrated reduced avidity of the 
lesion from SUVmax of 14.1 to 4.9. sVEGF remained low at 350pg/ml, and the 
paraprotein undetectable. This case demonstrates that PET avid lesions can 
persist despite there being a response to treatment and the importance of 
considering multiple factors when assessing response to therapy. The patient 
remains well, and demonstrated this by jogging into the clinic room on his last 
visit.  
 
 
POEMS syndrome is a devastating condition for many patients, unless prompt 
diagnosis and provision of effective treatment prevents significant disability and 
the multitude of associated features. Identification of a demyelinating peripheral 
neuropathy, a lambda light chain monoclonal plasma cell disorder and raised 
VEGF are key to making the diagnosis. Investigations identify focal from systemic 
disease, which guides subsequently highly effective treatment in the form of 
radiotherapy, chemotherapy or autologous peripheral stem cell transplantation.  
 
 
 
Learning points 
1) Not all patients with POEMS present with the classic features described in 
the acronym. 
2) We recommend all patients presenting with an inflammatory neuropathy 
to have appropriate investigations for the presence of a monoclonal 
plasma cell proliferative disorder, and if abnormal,consideration of VEGF. 
3) Patients are deemed to have focal or systemic disease based on the extent 
of monoclonal plasma cell dyscrasia, and this should guide subsequent 
treatment options.  
 
 
VEGF testing is performed currently at the Department of Neuroimmunology, at 
the National Hospital for Neurology and Neurosurgery, London and has a 
turnaround time of around 2 weeks. 
 
 
 
Table 1: Diagnostic criteria for POEMS syndrome 
 
Criteria  
Mandatory major criteria 1. Polyneuropathy  
2. Monoclonal plasma cell 
proliferative disorder  
Other Major criteria (one 
required) 
3. Castleman disease 
4. Sclerotic bone lesions 
5. Raised Vascular endothelial 
growth factor 
Minor criteria 6. Organomegaly (spleen/liver/ 
lymph nodes) 
7. Extravascular volume overload 
8. Endocrinopathy (adrenal, 
thyroid*, pituitary, gonadal, 
parathyroid, pancreatic*) 
9. Skin changes 
10. Papilloedema 
11. Thrombocytosis/polycythemia 
Other useful features  Clubbing, weight loss, hyperhidrosis, 
pulmonary hypertension/ restrictive 
lung disease, thrombotic diathesis, 
diarrhoea, low vitamin B12.  
 
*Due to high prevalence of thyroid disease and diabetes, this diagnosis alone is not sufficient to 
meet criteria for endocrinopathy. 
 
 
 
 
 
 
 
Table 2: History, examination and neurophysiological findings to distinguish 
POEMS neuropathy from CIDP 
 
Assessment   POEMS syndrome CIDP 
History  Length dependent 
sensory and motor 
neuropathy 
Patchy 
predominantly 
motor neuropathy 
with both proximal 
and distal features 
at onset 
  Presence of pain 
typical (65%) 17 
Pain atypical 
  Other multi-systemic 
symptoms present: 
Gynaecomastia 
Erectile dysfunction 
Multi systemic 
features less likely 
and unrelated 
Weight loss 
Skin changes 
Oedema  
History of DVT 
Examination General  Finding of lymph 
nodes, skin lesions, 
organomegaly, 
papilloedema, 
peripheral oedema 
Neuropathy likely in 
isolation 
Neuropathy Dramatic distal 
weakness, 
predominantly UL 
flexors> ext. LL 
DF>>PF. Early distal 
wasting.  
Evidence of 
proximal and distal 
weakness.  
Investigation Blood/urine for 
monoclonal 
protein 30,39 
Monoclonal IgA or 
IgG typical. IgM rare. 
Almost always 
lambda light chain 
MGUS in 10-20%. 
Distribution of 
classes and light 
chains balanced. 
Consider MAG and 
GM1. 
 Thrombocytosis 
30 
Seen in 54% patients Seen in 1.5% 
 VEGF Likely >2x ULN (ref 
range sVEGF 5-
771pg/ml) 
Almost never raised 
unless anaemia, 
renal failure. 
Unlikely ever 
>2xULN 
 Neurophysiology 
14,17,40 
Axonal and 
demyelinating. 
Preferential lower 
limbs, intermediate > 
distal nerve CV 
slowing.  
Conduction block 
(6%) and temporal 
dispersion unlikely. 
Less axonal loss. 
Patchy proximal and 
distal 
demyelination. 
Conduction block 
(23%) and temporal 
dispersion more 
common. 
 Nerve biopsy16,17 More axonal 
degeneration, diffuse 
myelinated fibre loss, 
increased epineurial 
blood vessles. 
Uncompacted myelin 
lamellae. 
Endoneurial 
inflammation, 
multifocal 
myelinated  nerve 
fibre loss. 
 Imaging Sclerotic and lytic 
bone lesions on 
xray/CT/PET  
Not routinely 
required. 
  Solitary lesion can 
represent 
 
plasmacytoma- 
needs biopsy to 
confirm 
Treatment  Steroids Mild response  Responsive* 
 Immune therapy Not responsive to 
IVIG/PLEX  
Responsive to 
IVIG/PLEX* 
 
 
*Note approximately 20% of CIDP patients will be poorly or unresponsive to 
steroids, IVIG and PLEX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Investigative work-up for suspected POEMS cases 
Feature Investigation Typical abnormality  
Polyneuropathy  NCS/EMG Axonal and demyelinating. Preferential lower 
limbs, intermediate > distal nerve CV slowing.  
Conduction block (6%) and temporal 
dispersion unlikely. 
Nerve biopsy** Not necessary if diagnosis is clear with 
elevated VEGF levels. Axonal degeneration, 
diffuse myelinated fibre loss, increased 
epineurial blood vessles. Uncompacted 
myelin lamellae. 
Cerebrospinal fluid** Albuminocytological dissociation. Normal cell 
count. Mild increase opening pressure. Not 
specific so not always necessary. 
Organomegaly  CT chest/abdomen/pelvis and Lymph node, spleen, liver 
 
*Endocrinopathy bloods should be taken fasted in the morning before breakfast 
** Test not essential for diagnosis, but useful 
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